Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 3 Interventional

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

ClinicalTrials.gov ID: NCT04976322

Public ClinicalTrials.gov record NCT04976322. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

Study identification

NCT ID
NCT04976322
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Biopharma SRL
Industry
Enrollment
760 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
16 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 26, 2021
Primary completion
Aug 6, 2030
Completion
Aug 6, 2030
Last update posted
Sep 3, 2026

2021 – 2030

United States locations

U.S. sites
33
U.S. states
19
U.S. cities
32
Facility City State ZIP Site status
Sl0046 50140 Birmingham Alabama 35294
Sl0046 50058 Avondale Arizona 85392
Sl0046 50662 Glendale Arizona 85306
Sl0046 50052 Phoenix Arizona 85032
Sl0046 50328 Tucson Arizona 85704
Sl0046 50383 Beverly Hills California 90210
Sl0046 50275 La Palma California 90623-1730
Sl0046 50316 San Leandro California 94578
Sl0046 50339 Denver Colorado 80230
Sl0046 50239 Brandon Florida 33511
Sl0046 50362 Gainesville Florida 32610
Sl0046 50681 Miami Florida 33172
Sl0046 50059 Ormond Beach Florida 32174
Sl0046 50324 Plantation Florida 33324
Sl0046 50329 Tampa Florida 33606
Sl0046 50698 Tampa Florida 33618
Sl0046 50368 Atlanta Georgia 30303
Sl0046 50240 Idaho Falls Idaho 83404
Sl0046 50699 Chicago Illinois 60616
Sl0046 50474 Hopkinsville Kentucky 42240-1746
Sl0046 50285 Lake Charles Louisiana 70605
Sl0046 50660 New Orleans Louisiana 70112
Sl0046 50015 Hagerstown Maryland 21740
Sl0046 50219 Detroit Michigan 48201
Sl0046 50273 Las Vegas Nevada 89128
Sl0046 50366 Canton New York 13617
Sl0046 50264 Manhasset New York 11030
Sl0046 50334 New York New York 10032
Sl0046 50238 Charlotte North Carolina 28211
Sl0046 50147 Hershey Pennsylvania 17033
Sl0046 50001 Jackson Tennessee 38305
Sl0046 50418 Colleyville Texas 76034
Sl0046 50050 Beckley West Virginia 25801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04976322, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2026 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04976322 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →